Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06126562
Other study ID # LNLN-I-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 31, 2023
Est. completion date December 15, 2023

Study information

Verified date December 2023
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a randomized, open-label parallel design and single centre study conducted at the 1st hospital affiliated to Jilin University. Approximately 24 healthy Chinese volunteers, male and female will be recruited and divided into two equal groups (12 subjects per dose). The primary objective of this study is to evaluate the pharmacokinetic profile of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects. The secondary objective is to evaluate the safety of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 15, 2023
Est. primary completion date November 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Aged 18-45 years (both inclusive) at the time of signing the informed consent form (ICF), regardless of gender; - Male subjects body weight = 50 kg and female subjects body weight = 45 kg, with a body mass index (BMI) of 18-28 kg/m2 (both inclusive); - No clinically significant findings in medical history, physical examination, 12-lead ECG, vital signs, laboratory tests, etc.; - Normal clinical laboratory test values at screening and baseline (Day 1) or judged as not clinically significant by the investigator and/or sponsor; - Alanine aminotransferase = 1.1 × upper limit of normal (ULN), aspartate aminotransferase = 1.2 × ULN; normal renal function, estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m2 at screening. - Subjects need to understood the study, agree to voluntarily participate in the study, to comply with the study requirements, and provide written informed consent; - Female subjects of childbearing potential must agree to use 2 highly effective methods of contraception, barrier contraception, during the study and within 30 days after one of which must be the study treatment. Female subjects must have a negative serum pregnancy test at screening and baseline (Day 1). - Male subjects and their female partners of childbearing potential must agree to use 2 highly effective methods of contraception (as defined above), one of which must be a barrier method, during the study and for 90 days after receiving the study drug. Exclusion Criteria: - History or evidence of respiratory, circulatory, endocrine, urinary, digestive, immunological, reproductive, hematological, neurological, or psychiatric disorders, especially any history that may affect drug absorption, distribution, metabolism, and excretion. - Subjects who are positive for any of the following: hepatitis B virus surface antigen (HBs-Ag), hepatitis C virus antibody (anti-HCV), human immunodeficiency virus antibody (anti-HIV), and treponema pallidum antibody (anti-TP). - Subjects with any of the following conditions within 6 months prior to screening: Unstable body weight, Women with irregular menstruation or ovulation, including but not limited to women with Stein-Leventhal syndrome and perimenopausal women with abnormal ovulation, History of osteoporosis or fracture, History of oedema peripheral at any site, History of gallbladder disease, including but not limited to cholelithiasis, and cholecystitis, History of hypoglycemia or events highly suspicious of hypoglycaemia. - Current tissue dysplasia or history of malignancy (including lymphoma and leukemia) within the past 5 years, except for successfully cured non-metastatic basal cell carcinoma or squamous cell carcinoma or localized cervical carcinoma in situ. - Pregnant, lactating women, or women planning to become pregnant during the study or within 30 days of study drug administration. - Treatment with another study drug or device within 3 months before study drug administration; or less than 5 half-lives from treatment with another study drug or device at screening, whichever is longer. - Known hypersensitivity or intolerance to lanifibranor or any of the excipients, and allergic constitution. - Consumption of more than 28 units of ethanol per week, or a history of alcohol abuse, at any time within 6 months prior to study drug administration. - Smoking more than 5 cigarettes per day or consuming an equivalent amount of nicotine or nicotine-containing products within 6 months before screening, or an inability to discontinue the use of any tobacco products during the study. - Taking prescription drugs (excluding oral and other contraceptives [e.g., long-acting formulations, transdermal contraceptives, and intrauterine devices]), including nonsteroidal anti-inflammatory drugs, sucralfate, drugs known to decrease metabolism or increase bioavailability, traditional Chinese medicine preparations, melatonin, or other nutritional supplements, within 14 days or 5 half-lives (whichever is longer) before study drug administration, or taking over-the-counter drugs, vitamins, or supplements (including cod-liver oil) within 7 days before study drug administration. - Consuming products containing alcohol, caffeine, or xanthines, Seville oranges, and grapefruit or grapefruit juice within 72 hours prior to study drug administration. - Engagement in strenuous activity (e.g., exercise) within 96 h (4 days) before admission to the clinical research unit (CRU) and throughout the study. - Donation of more than 500 mL of blood or significant blood loss within 90 days prior to admission to the CRU. - History or evidence of poor venous access or hemorrhagic disorder. - History of drug use, drug abuse, or positive urine drug test. - Any condition that, as determined by the investigator, may pose a safety risk to the subject during the study or may interfere with the study's conduct, or the investigator believes that the subject may not be able to complete the study or comply with its requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lanifibranor
Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum concentration (Cmax) Maximum plasma drug concentration Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Area under the plasma concentration-time curve The area enclosed by the blood concentration curve to the timeline Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Time to maximum concentration (Tmax) The time required to reach peak concentration after administration Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Apparent volume of distribution (Vd/F) Drug dose reach a dynamic balance in the body the body and blood drug concentration ratio constant Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Apparent plasma clearance (CL/F) The volume of plasma with drug cleared per unit of time Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Plasma elimination half-life (t1/2) The time it takes for the terminal phase blood concentration to drop by half Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Time to maximum concentration at steady state (Tmax, ss) in Part B The time required to reach peak steady-state concentration after administration Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Maximum concentration at steady state (Cmax, ss) in Part B The maximum blood drug concentration that occurs after stabilization Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Minimum concentration at steady state (Cmin, ss) in Part B The minimum blood drug concentration that occurs after stabilization Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Primary Average steady-state plasma concentration (Cav, ss) in Part B The plasma concentration at which the rate of administration and rate of elimination are in equilibrium. Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Secondary Adverse event rate The occurrence rate of all adverse events (AEs), and adverse events of special interest (AESI) and serious adverse events (SAEs). Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
Secondary Adverse event rate The occurrence rate of abnormal clinical laboratory tests, vital signs, physical examination and 12 lead-electrocardiogram (ECG). Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, 120, 168 hours after dose.
See also
  Status Clinical Trial Phase
Completed NCT04531150 - Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects Phase 1
Completed NCT03437265 - A Pharmacokinetic Study of PLENVU® in Healthy Subjects Phase 1
Completed NCT03979989 - Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol) Phase 1
Completed NCT00743912 - Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers Phase 1
Not yet recruiting NCT05367011 - Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
Completed NCT00745264 - Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise Phase 1
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A
Completed NCT01082796 - Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects N/A
Terminated NCT02696954 - Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects Phase 1/Phase 2
Recruiting NCT03714568 - Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants. Phase 1
Recruiting NCT04080895 - Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects Phase 1
Active, not recruiting NCT04735913 - Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Early Phase 1
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT00681395 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium Phase 1
Completed NCT04617509 - A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Phase 1
Terminated NCT03059511 - Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants Phase 1
Withdrawn NCT05938608 - A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Phase 1
Completed NCT01091532 - A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. Phase 1
Completed NCT03951402 - Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women Phase 1
Completed NCT03882762 - A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol Phase 1